Memantin Aaa-Pharma

Memantine Hydrochloride, the active ingredient in Memantin Aaa-Pharma, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease and related dementia in adult patients.

GNH USA supplies Memantin Aaa-Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global distribution network ensures timely delivery and compliance with local regulatory requirements.

Memantin Aaa-Pharma is used within the Alzheimer’s disease therapeutic pathway to address cognitive decline in affected patients.

Alzheimer's disease (moderate to severe): improves cognition and daily functional abilities. Dementia associated with Alzheimer’s: may slow the progression of functional decline. Behavioral symptoms of dementia: can help reduce agitation and aggression in some patients.

Memantin Aaa-Pharma may be associated with a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Fatigue

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (e.g., rash, angioedema) - Hallucinations or psychosis - Suicidal thoughts or behavior - Cardiac arrhythmias - Hepatic injury

Before initiating therapy, clinicians should consider several safety aspects.

Assess renal function: adjust dose or avoid use in severe renal impairment. Monitor blood pressure: watch for hypertension, especially in patients with cardiovascular disease. Avoid use in patients with known hypersensitivity to memantine or excipients. Use with caution in patients with a history of seizures. Review concomitant NMDA‑targeting agents: avoid additive neurotoxicity. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantin Aaa-Pharma can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism may cause excessive CNS depression. - Other NMDA antagonists: heightened risk of neurologic side effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish memantine's cognitive benefits. - Central nervous system depressants (e.g., benzodiazepines): may enhance dizziness or sedation. - Diuretics: may alter plasma concentrations of memantine.